oxandrolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anabolic steroids 2011 53-39-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxandrolone
  • anavar
  • lonavar
  • oxandren
  • oxandrin
  • vasorome
A synthetic hormone with anabolic and androgenic properties.
  • Molecular weight: 306.45
  • Formula: C19H30O3
  • CLOGP: 2.96
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -4.34
  • ROTB: 0
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 97 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
July 21, 1964 FDA CREALTA PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hereditary angioedema 40.24 36.04 8 158 7554 63481302

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Testicular atrophy 51.86 41.76 8 262 584 34956077
Muscle mass 50.08 41.76 7 263 257 34956404

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Testicular atrophy 58.87 34.86 8 399 363 79743618
Muscle mass 49.00 34.86 7 400 457 79743524

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A14AA08 ALIMENTARY TRACT AND METABOLISM
ANABOLIC AGENTS FOR SYSTEMIC USE
ANABOLIC STEROIDS
Androstan derivatives
MeSH PA D045930 Anabolic Agents
MeSH PA D000728 Androgens
MeSH PA D006728 Hormones
CHEBI has role CHEBI:50113 androgene

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Catabolic Process indication
Turner syndrome off-label use 38804009 DOID:3491
Hypercholesterolemia contraindication 13644009
Nephrotic syndrome contraindication 52254009 DOID:1184
Peliosis hepatis contraindication 58008004 DOID:914
Blood coagulation disorder contraindication 64779008 DOID:1247
Hypercalcemia contraindication 66931009 DOID:12678
Arteriosclerotic vascular disease contraindication 72092001
Heart failure contraindication 84114007 DOID:6000
Kidney disease contraindication 90708001 DOID:557
Cholestatic hepatitis contraindication 95556007
Neoplasm of liver contraindication 126851005 DOID:3571
Neoplasm of prostate contraindication 126906006 DOID:10283
Hypoalphalipoproteinemia contraindication 190785000
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Breast Carcinoma in Males contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor AGONIST IC50 9.09 CHEMBL CHEMBL

External reference:

IDSource
4018126 VUID
N0000146464 NUI
D00462 KEGG_DRUG
4018126 VANDF
C0029995 UMLSCUI
CHEBI:7820 CHEBI
CHEMBL1200436 ChEMBL_ID
DB00621 DRUGBANK_ID
D010074 MESH_DESCRIPTOR_UI
5878 PUBCHEM_CID
7092 IUPHAR_LIGAND_ID
1325 INN_ID
7H6TM3CT4L UNII
224933 RXNORM
4491 MMSL
5209 MMSL
91416 MMSL
d00566 MMSL
001258 NDDF
126128007 SNOMEDCT_US
2679000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 0245-0271 TABLET 2.50 mg ORAL ANDA 25 sections
oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 0245-0272 TABLET 10 mg ORAL ANDA 24 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-301 TABLET 2.50 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-301 TABLET 2.50 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-301 TABLET 2.50 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-302 TABLET 10 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-302 TABLET 10 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 49884-302 TABLET 10 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 63629-7603 TABLET 2.50 mg ORAL ANDA 20 sections
Oxandrolone HUMAN PRESCRIPTION DRUG LABEL 1 63629-7603 TABLET 2.50 mg ORAL ANDA 20 sections